[Form 3] Autolus Therapeutics plc Initial Statement of Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Autolus Therapeutics plc director John E. Berriman filed an initial ownership report showing his current equity position. He directly holds 136,331 Ordinary Shares, which may be represented by American Depositary Shares, each currently equal to one ordinary share.
He also holds several share options over American Depositary Shares, with exercise prices ranging from $2.32 to $30.24 per share and expirations between February 2028 and June 2035. Footnotes state that certain options are fully vested and exercisable and that one grant vests in twelve equal monthly installments commencing on July 26, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Berriman John E
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 15,698 shares (Direct);
Ordinary Shares — 136,331 shares (Direct)
Footnotes (1)
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one ordinary share. Fully vested and exercisable. This option vested or vests in twelve equal monthly installments commencing on July 26, 2025.
